FibroBiologics (FBLG) announced the publication of an opinion editorial authored by company leadership that presents the scientific case for fibroblast cells’ therapeutic advantages compared to stem cell therapies. The article, titled “Fibroblast Cells vs. Stem Cells: A Superior Option for Chronic Disease Therapy,” was authored by Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics, and Hamid Khoja, Ph.D., Chief Scientific Officer. The editorial presents a comprehensive review of published research and FibroBiologics’ long-term internal scientific studies supporting the advantages that fibroblast cells offer over stem cells in treating chronic diseases, including faster proliferation rates, superior sourcing capabilities, and enhanced immune modulation properties for conditions such as multiple sclerosis, rheumatoid arthritis, and wound healing applications.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics announces IND-enabling updates from psoriasis research program
- FibroBiologics announces advancements in Bone Marrow Organoid platform
- FibroBiologics Faces Nasdaq Delisting Notice
- FibroBiologics Reports Increased Losses Amid R&D Expansion
- Positive Outlook on FibroBiologics, Inc. Due to Strategic Positioning and Clinical Progress in Fibroblast-Based Therapies